{"title":"Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy.","authors":"Kuan-Chang Lai, Yen-Hao Chen, Yi-Ping Hung, Nai-Jung Chiang, Ming-Huang Chen, San-Chi Chen","doi":"10.1007/s12072-024-10728-9","DOIUrl":"10.1007/s12072-024-10728-9","url":null,"abstract":"<p><strong>Background/purpose: </strong>Recently, anti-programmed cell death protein-1 (anti-PD-1) and anti-PD-L1 therapies were approved for hepatocellular carcinoma (HCC). However, the effectiveness of rechallenging with one immune checkpoint inhibitor (ICI) after failure of another remains unclear. This study explores the efficacy and safety of anti-PD-L1 rechallenge in patients who failed anti-PD-1 therapy.</p><p><strong>Methods: </strong>From January 2016 to December 2023, 65 advanced HCC patients previously treated with anti-PD-1 therapy were retrospectively enrolled and rechallenged with durvalumab (480 mg IV every 2 weeks).</p><p><strong>Results: </strong>Overall, 86.2% of patients received nivolumab and 13.8% pembrolizumab as prior anti-PD-1 therapy. The overall response rate (ORR) to durvalumab was 13.8%. Patients who responded to prior anti-PD-1 had a higher ORR compared to non-responders (31.3% vs. 8.7%, p = 0.04). Patients with any grade of immune-related adverse events (irAEs) from durvalumab had a higher ORR than those without irAEs (35.3% vs. 6.7%, p = 0.01). The median PFS was 5.4 months, and the median OS was 9.6 months. Responders to prior anti-PD-1 showed longer OS (33.9 vs. 8.2 months, p < 0.01) and a trend toward longer PFS (13.8 vs. 4.9 months, p = 0.07) compared to non-responders. Multivariate analysis identified prior anti-PD-1 response (HR: 0.31) as the only protective factor for death. Common irAEs were skin toxicity (13.8%) and hepatitis (7.7%); no correlation was found between irAEs from prior anti-PD-1 and durvalumab treatment.</p><p><strong>Conclusion: </strong>This study provides the first, concrete evidence that durvalumab rechallenge is effective for HCC patients who are refractory to anti-PD-1 therapy, especially for those who previously responded to anti-PD-1 treatment.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1804-1814"},"PeriodicalIF":5.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11632046/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2024-12-01Epub Date: 2024-08-27DOI: 10.1007/s12072-024-10724-z
Dali Xiong, Jiaran Li, Shuanghu Yuan
{"title":"Is laparoscopic hepatectomy superior to radiofrequency ablation in treating small hepatocellular carcinoma?","authors":"Dali Xiong, Jiaran Li, Shuanghu Yuan","doi":"10.1007/s12072-024-10724-z","DOIUrl":"10.1007/s12072-024-10724-z","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1815-1816"},"PeriodicalIF":5.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2024-12-01Epub Date: 2024-11-15DOI: 10.1007/s12072-024-10739-6
Akash Shukla, Don C Rockey, Patrick S Kamath, David E Kleiner, Ankita Singh, Arun Vaidya, Abraham Koshy, Ashish Goel, A Kadir Dökmeci, Babulal Meena, Cyriac Abby Philips, Chhagan Bihari Sharma, Diana A Payawal, Dong Joon Kim, Gin-Ho Lo, Guohong Han, Huma Qureshi, Ian R Wanless, Jidong Jia, Jose D Sollano, Mamun Al Mahtab, Mark Dhinesh Muthiah, Mark W Sonderup, Mendez Sanchez Nahum, Mohamed Ismail Bin Merican, Necati Ormeci, Norifumi Kawada, Rajender Reddy, R K Dhiman, Rino Gani, Saeed S Hameed, Sidharth Harindranath, Wasim Jafri, Xiaolong Qi, Yogesh Kumar Chawla, Yoshihiro Furuichi, Ming-Hua Zheng, Shiv Kumar Sarin
{"title":"Non-cirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and management.","authors":"Akash Shukla, Don C Rockey, Patrick S Kamath, David E Kleiner, Ankita Singh, Arun Vaidya, Abraham Koshy, Ashish Goel, A Kadir Dökmeci, Babulal Meena, Cyriac Abby Philips, Chhagan Bihari Sharma, Diana A Payawal, Dong Joon Kim, Gin-Ho Lo, Guohong Han, Huma Qureshi, Ian R Wanless, Jidong Jia, Jose D Sollano, Mamun Al Mahtab, Mark Dhinesh Muthiah, Mark W Sonderup, Mendez Sanchez Nahum, Mohamed Ismail Bin Merican, Necati Ormeci, Norifumi Kawada, Rajender Reddy, R K Dhiman, Rino Gani, Saeed S Hameed, Sidharth Harindranath, Wasim Jafri, Xiaolong Qi, Yogesh Kumar Chawla, Yoshihiro Furuichi, Ming-Hua Zheng, Shiv Kumar Sarin","doi":"10.1007/s12072-024-10739-6","DOIUrl":"10.1007/s12072-024-10739-6","url":null,"abstract":"<p><p>Since the Asian Pacific Association for the Study of the Liver (APASL) published guidelines on non-cirrhotic portal fibrosis/idiopathic portal hypertension in 2007, there has been a surge in new information, especially with the introduction of the term porto-sinusoidal vascular disorder (PSVD). Non-cirrhotic intra-hepatic causes of portal hypertension include disorders with a clearly identifiable etiology, such as schistosomiasis, as well as disorders with an unclear etiology such as non-cirrhotic portal fibrosis (NCPF), also termed idiopathic portal hypertension (IPH). This entity is being increasingly recognized as being associated with systemic disease and drug therapy, especially cancer therapy. An international working group with extensive expertise in portal hypertension was assigned with formulating consensus guidelines to clarify the definition, diagnosis, histological features, natural history, and management of NCPF/IPH, especially in the context of PSVD. The guidelines were prepared based on evidence from existing published literature. Whenever there was paucity of evidence, expert opinion was included after detailed deliberation. The goal of this manuscript, therefore, is to enhance the current understanding and help create global consensus on the issues surrounding NCPF/IPH.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1684-1711"},"PeriodicalIF":5.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2024-12-01Epub Date: 2024-11-21DOI: 10.1007/s12072-024-10732-z
George Lau, Shuntaro Obi, Jian Zhou, Ryosuke Tateishi, Shukui Qin, Haitao Zhao, Motoyuki Otsuka, Sadahisa Ogasawara, Jacob George, Pierce K H Chow, Jianqiang Cai, Shuichiro Shiina, Naoya Kato, Osamu Yokosuka, Kyoko Oura, Thomas Yau, Stephen L Chan, Ming Kuang, Yoshiyuki Ueno, Minshan Chen, Ann-Lii Cheng, Gregory Cheng, Wan-Long Chuang, Oidov Baatarkhuu, Feng Bi, Yock Young Dan, Rino A Gani, Atsushi Tanaka, Wasim Jafri, Ji-Dong Jia, Jia-Horng Kao, Kiyoshi Hasegawa, Patrick Lau, Jeong Min Lee, Jun Liang, Zhenwen Liu, Yinying Lu, Hongming Pan, Diana A Payawal, Salimur Rahman, Jinsil Seong, Feng Shen, Gamal Shiha, Tianqiang Song, Hui-Chuan Sun, Tsutomu Masaki, Ekaphop Sirachainan, Lai Wei, Jin Mo Yang, Jose D Sallano, Yanqiao Zhang, Tawesak Tanwandee, AKadir Dokmeci, Shu-Sen Zheng, Jia Fan, Sheung-Tat Fan, Shiv Kumar Sarin, Masao Omata
{"title":"APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.","authors":"George Lau, Shuntaro Obi, Jian Zhou, Ryosuke Tateishi, Shukui Qin, Haitao Zhao, Motoyuki Otsuka, Sadahisa Ogasawara, Jacob George, Pierce K H Chow, Jianqiang Cai, Shuichiro Shiina, Naoya Kato, Osamu Yokosuka, Kyoko Oura, Thomas Yau, Stephen L Chan, Ming Kuang, Yoshiyuki Ueno, Minshan Chen, Ann-Lii Cheng, Gregory Cheng, Wan-Long Chuang, Oidov Baatarkhuu, Feng Bi, Yock Young Dan, Rino A Gani, Atsushi Tanaka, Wasim Jafri, Ji-Dong Jia, Jia-Horng Kao, Kiyoshi Hasegawa, Patrick Lau, Jeong Min Lee, Jun Liang, Zhenwen Liu, Yinying Lu, Hongming Pan, Diana A Payawal, Salimur Rahman, Jinsil Seong, Feng Shen, Gamal Shiha, Tianqiang Song, Hui-Chuan Sun, Tsutomu Masaki, Ekaphop Sirachainan, Lai Wei, Jin Mo Yang, Jose D Sallano, Yanqiao Zhang, Tawesak Tanwandee, AKadir Dokmeci, Shu-Sen Zheng, Jia Fan, Sheung-Tat Fan, Shiv Kumar Sarin, Masao Omata","doi":"10.1007/s12072-024-10732-z","DOIUrl":"10.1007/s12072-024-10732-z","url":null,"abstract":"<p><p>In Asia-Pacific region, hepatocellular carcinoma is a serious health threat attributing to over 600,000 deaths each year and account for over 70% of global cases. Clinically, the major unmet needs are recurrence after curative-intent surgery, liver transplantation or local ablation and disease progression in those with hepatocellular carcinoma not eligible for resection or failed locoregional therapy. In the recent few years, new targeted therapy and immune-checkpoint inhibitors have been registered as systemic therapy to address these issues. Notably, new forms of systemic therapy, either as first-line or second-line therapy for unresectable hepatocellular or those not eligible for locoregional therapy, are now available. New data is also emerging with the use of systemic therapy to prevent hepatocellular carcinoma recurrence after curative-intent resection or local ablation therapy and to retard disease progression after locoregional therapy. In the future, further implementation of immune-checkpoint inhibitors and other forms of immunotherapy are expected to bring a new paradigm to the management of hepatocellular carcinoma. New insight related to immune-related adverse events with the use of immunotherapy has allso enabled optimization of the therapeutic approach to patients with hepatocellular carcinoma. The purpose of this clinical practice guideline is to provide an up-to-date recommendation based on clinical evidence and experience from expert Asia-Pacific key opinion leaders in the field of hepatocellular carcinoma. Three key questions will be addressed, namely: (1) Which patients with hepatocellular carcinoma should be considered for systemic therapy? (2) Which systemic therapy should be used? (3) How should a patient planned for immune checkpoint-based systemic therapy be managed and monitored?</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1661-1683"},"PeriodicalIF":5.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2024-12-01Epub Date: 2024-08-13DOI: 10.1007/s12072-024-10717-y
Ruobin Zong, Yan Zheng, Yufei Yan, Wenao Sun, Liangyi Kong, Yating Huang, Yujie Liu, Chaochen Jiang, Jie Ping, Changyong Li
{"title":"Mesenchymal stem cells-derived exosomes alleviate liver fibrosis by targeting Hedgehog/SMO signaling.","authors":"Ruobin Zong, Yan Zheng, Yufei Yan, Wenao Sun, Liangyi Kong, Yating Huang, Yujie Liu, Chaochen Jiang, Jie Ping, Changyong Li","doi":"10.1007/s12072-024-10717-y","DOIUrl":"10.1007/s12072-024-10717-y","url":null,"abstract":"<p><strong>Background & aims: </strong>Despite increasing knowledge regarding the cellular and molecular mechanisms of liver fibrogenesis, there is currently no approved drug for the treatment of liver fibrosis. Mesenchymal stem cells (MSCs) are multipotent progenitor cells representing an attractive therapeutic tool for tissue damage and inflammation. This study was designed to determine the protective effect and underlying mechanism of human umbilical cord-derived MSCs (UC-MSCs) on thioacetamide-induced liver fibrosis.</p><p><strong>Methods: </strong>Liver fibrosis was induced in mice by intraperitoneal injection of thioacetamide (TAA). Some mice were then given injection of UC-MSCs or UC-MSCs-derived exosomes (UC-MSCs-Exo) via the tail vein. Liver tissues were collected for histologic analysis.</p><p><strong>Results: </strong>We found that administration of UC-MSCs significantly reduced serum alanine aminotransferase and aspartate aminotransferase levels, and attenuated hepatic inflammation and fibrosis. Moreover, the therapeutic effect of UC-MSCs-derived exosomes was similar to that of UC-MSCs. Intriguingly, UC-MSCs-Exo treatment downregulated the expression of smoothened (SMO), a fundamental component of Hedgehog signaling which plays a critical role in fibrogenesis, and subsequently inhibited the activation of hepatic stellate cells, a central driver of fibrosis in experimental and human liver injury. Furthermore, the anti-inflammatory and anti-fibrotic effects of UCMSCs- Exo was reversed by the SMO agonist SAG treatment in mice.</p><p><strong>Conclusion: </strong>Our findings suggest that UC-MSCs-Exo exert therapeutic effects on liver fibrosis, at least in part, through inhibiting the Hedgehog/SMO signaling pathway.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1781-1791"},"PeriodicalIF":5.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2024-12-01Epub Date: 2024-11-20DOI: 10.1007/s12072-024-10751-w
George Lau
{"title":"Rechallenge with immune checkpoint inhibitors therapy for patients with HCC-lot more to learn.","authors":"George Lau","doi":"10.1007/s12072-024-10751-w","DOIUrl":"10.1007/s12072-024-10751-w","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1712-1714"},"PeriodicalIF":5.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2024-12-01Epub Date: 2024-08-28DOI: 10.1007/s12072-024-10721-2
Mingqian Jiang, Ziyan Pan, Jacob George, Mohammed Eslam
{"title":"Clinical features and mortality outcomes of patients with MASLD only compared to those with MAFLD and MASLD.","authors":"Mingqian Jiang, Ziyan Pan, Jacob George, Mohammed Eslam","doi":"10.1007/s12072-024-10721-2","DOIUrl":"10.1007/s12072-024-10721-2","url":null,"abstract":"<p><strong>Background and aims: </strong>The applicability of the proposed metabolic dysfunction-associated steatotic liver disease (MASLD) definition has not been validated. We aimed to characterize the profiles and long-term survival of people meeting the criteria for MASLD, but not that of metabolic dysfunction-associated fatty liver disease (MAFLD), i.e. MASLD only.</p><p><strong>Methods: </strong>Using data from the Third National Health and Nutrition Examination Survey (NHANES III) 1988-1994, 7791 adult participants were included and categorized into four distinct groups: no SLD, non-MAFLD MASLD, MASLD-MAFLD, and cryptogenic SLD (steatosis without metabolic dysfunction).</p><p><strong>Results: </strong>Participants in the MASLD-only group were younger and had better metabolic profiles and fibrosis degree compared to those with MASLD-MAFLD and those with no SLD. Their profiles were comparable to those with cryptogenic SLD. Similarly, the MASLD-only group tend to have lower cumulative incidence of all-cause and cardiovascular mortality. Clustering analysis showed that MASLD only clusters differently from individuals with MASLD-MAFLD.</p><p><strong>Conclusions: </strong>MASLD only is a distinct clinical group with substantial heterogeneity compared to those captured using the MAFLD criteria.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1731-1739"},"PeriodicalIF":5.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142080034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2024-12-01Epub Date: 2024-07-02DOI: 10.1007/s12072-024-10688-0
Nan Zhang, Zhaohui Li, Yutao Liu, Xiaohua Shi, Di Shi, Yue Li, Xiaoyan Si, Ziyu Xun, Jing Shao, Haitao Zhao, Hanping Wang
{"title":"Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics.","authors":"Nan Zhang, Zhaohui Li, Yutao Liu, Xiaohua Shi, Di Shi, Yue Li, Xiaoyan Si, Ziyu Xun, Jing Shao, Haitao Zhao, Hanping Wang","doi":"10.1007/s12072-024-10688-0","DOIUrl":"10.1007/s12072-024-10688-0","url":null,"abstract":"<p><strong>Background: </strong>The management of severe immune-related hepatotoxicity (irH) needs to be further optimized. This study aims to analyze the clinical characteristics of severe irH; improve the therapeutic strategy, especially salvage treatment in steroid-refractory irH; and determine the safety of immune checkpoint inhibitor (ICPi)-rechallenge.</p><p><strong>Methods: </strong>This multicenter retrospective study included patients who developed severe irH and those without irH after immunotherapy between May 2019 and June 2023. Propensity score matching was used to match these two cohorts with similar baseline characteristics.</p><p><strong>Results: </strong>Among 5,326 patients receiving ICPis, 51 patients developed severe irH. irH occurred after a median duration of 36 days and a median of two doses after the first ICPi administration. Patients receiving PD-L1 inhibitors faced a lower risk of developing severe irH. A higher dose of glucocorticoids (GCS) was administered to grade 4 irH than grade 3 irH. For steroid-sensitive patients, grade 4 irH individuals received a higher dosage of GCS than those with grade 3 irH, with no difference in time to resolution. Meanwhile, a significantly higher dose of GCS plus immunosuppression was needed in the steroid-refractory group. Liver biopsy of the steroid-refractory patients exhibited heterogeneous histological features. Twelve patients were retreated with ICPi. No irH reoccurred after a median follow-up of 9.3 months.</p><p><strong>Conclusion: </strong>irH requires multidimensional evaluation. PD-L1 inhibitors correlated with a lower risk of severe irH. Grade 4 irH demands a higher dose of GCS than recommended. Pathology may guide the salvage treatment for steroid-refractory irH. ICPi rechallenge in severe irH is feasible and safe.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1770-1780"},"PeriodicalIF":5.9,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11632075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xue Gong, Min Yang, Zixin Zhang, Tong Qiu, Jiangyuan Zhou, Wei Shan, Xuepeng Zhang, Yuru Lan, Pingqian Bao, Zilong Zhou, Congxia Yang, Yujia Zhang, Tianliang Li, Jing Guo, Jun Guo, Guoyan Lu, Feiteng Kong, Yongbo Zhang, Siyuan Chen, Yi Ji
{"title":"Clinical characteristics and managements of congenital hepatic hemangioma: a cohort study of 211 cases.","authors":"Xue Gong, Min Yang, Zixin Zhang, Tong Qiu, Jiangyuan Zhou, Wei Shan, Xuepeng Zhang, Yuru Lan, Pingqian Bao, Zilong Zhou, Congxia Yang, Yujia Zhang, Tianliang Li, Jing Guo, Jun Guo, Guoyan Lu, Feiteng Kong, Yongbo Zhang, Siyuan Chen, Yi Ji","doi":"10.1007/s12072-024-10756-5","DOIUrl":"https://doi.org/10.1007/s12072-024-10756-5","url":null,"abstract":"<p><strong>Background: </strong>Hepatic hemangiomas can be classified into three morphologic patterns: focal (congenital hepatic hemangiomas [CHHs]), multifocal, and diffuse. We aimed to identify the clinical characteristics of CHH and evaluate the changes in CHH management at our institution over the last 2 decades.</p><p><strong>Methods: </strong>This was a retrospective cohort study of children diagnosed with CHH who were managed at 8 investigation sites. The primary outcome was changes in CHH size in patients at the last follow-up. The primary exposure of interest was management modality in 2 study periods (2003-2012 versus 2013-2022).</p><p><strong>Results: </strong>Two hundred and eleven patients were analyzed. Four different subtypes of CHH were identified. Rapidly involuting CHH patients had complete involution/nearly complete involution, with a median age of 12.0 months. Noninvoluting CHH presented no change in CHH size. Partially involuting CHH patients presented with partial involution and had a stable tumor size at a median age of 16.0 months. Postnatally proliferating CHHs had an initial postnatal increase in CHH lesion size and underwent involution at a median age of 27.0 months. Further analysis revealed that management strategies for CHHs have shifted over time, with the proportion of patients receiving expectant management increasing from 35.4% before 2013 to 77.7% after 2013 (difference, 42.3%; 95% confidence interval 29.3-53.3%). The survival rate of patients with CHH was high (98.6%).</p><p><strong>Conclusions: </strong>We documented 4 subtypes of CHHs. We found that expectant management strategies have increasingly replaced invasive interventions in patients with CHH over the past 2 decades.</p><p><strong>Research registration unique identifying number (uin): </strong>We have already registered at Clinicaltrials.gov. The UIN number is NCT03331744.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Semaglutide and the risk of adverse liver outcomes in patients with nonalcoholic fatty liver disease and type 2 diabetes: a multi-institutional cohort study.","authors":"Chia-Chih Kuo, Min-Hsiang Chuang, Chun-Hsien Li, Po-Yu Huang, Hsing-Tao Kuo, Chih-Cheng Lai","doi":"10.1007/s12072-024-10752-9","DOIUrl":"https://doi.org/10.1007/s12072-024-10752-9","url":null,"abstract":"<p><strong>Background: </strong>Semaglutide has shown potential liver benefits in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D). However, no direct comparisons have been made between semaglutide and other antidiabetic medications, including sodium-glucose cotransporter-2 inhibitors (SGLT2i), thiazolidinediones (TZD), and dipeptidyl peptidase-4 inhibitors (DPP-4i), regarding liver outcomes in patients with both NAFLD and T2D.</p><p><strong>Methods: </strong>This retrospective cohort study utilized the TriNetX electronic health record database, a multinational and multi-institutional database. Adults with NAFLD and T2D who received their first prescription for either semaglutide or other antidiabetic medications were included. New users of semaglutide were matched 1:1 via propensity score matching with users of SGLT2i, DPP-4i, and TZD. The primary outcome was major adverse liver outcome (MALO), a composite end point consisting of decompensated cirrhosis, hepatocellular carcinoma, and liver transplantation. Secondary outcomes included the individual components of MALO and all-cause mortality.</p><p><strong>Results: </strong>A total of 648,070 adult patients with T2D and NAFLD were identified, and patients were categorized into three different comparison groups based on their drug of interest. Semaglutide was associated with a lower risk of MALO compared to SGLT2i (adjusted hazard ratio [aHR], 0.73; 95% CI 0.60-0.88), DPP-4i (aHR, 0.72; 95% CI 0.56-0.86), and TZD (aHR, 0.76; 95% CI 0.56-0.99). Additionally, semaglutide was linked to a lower risk of all-cause mortality compared to SGLT2i (aHR, 0.62; 95% CI 0.53-0.72), DPP-4i (aHR, 0.42; 95% CI 0.36-0.49), and TZD (aHR, 0.67; 95% CI 0.54-0.83).</p><p><strong>Conclusion: </strong>Semaglutide is associated with better liver outcomes and a lower risk of all-cause mortality compared to SGLT2i, DPP-4i, and TZD in patients with NAFLD and T2D.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142728010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}